Trial Profile
A randomized, open label, phase II study comparing efficacy of pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant Non-Small Cell Lung Cancer patients who have failed first-line EGFR TKI
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2016
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Jul 2016 New trial record
- 07 Jun 2016 Primary endpoint has not been met. (PFS), as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology